

# PD-L1 Testing Algorithm


[Click here for topics associated with this algorithm](#)

**Abbreviations**

ESCC	Esophageal squamous cell carcinoma
HNSCC	Head and neck squamous cell carcinoma
NSCLC	Non-small cell lung cancer
MMR	Mismatch repair
MSI	Microsatellite instability
PD-L1	Programmed death-ligand 1
TNBC	Triple-negative breast cancer

**INDICATIONS FOR TESTING**  
 Predict response to PD-L1 inhibitors in patients with varied malignancies

PD-L1 inhibitor therapy<sup>a</sup>



<sup>a</sup>This algorithm may be used for the following PD-L1 inhibitor therapies: cemiplimab-rwlc (LIBTAYO), nivolumab (OPDIVO), nivolumab (OPDIVO) plus ipilimumab (YERVOY), and pembrolizumab (KEYTRUDA). PD-L1 SP142 and PD-L1 SP263 for treatment with atezolizumab (TECENTRIQ) are also available for ordering at some laboratories.

<sup>b</sup>MSI/MMR-deficient tumors: KEYTRUDA has been approved for these tumors, irrespective of site. No PD-L1 testing is required. Testing to establish MSI/MMR-deficient status is required.

<sup>c</sup>MSI/MMR-deficient colorectal carcinomas: OPDIVO has been approved for these cancers. No PD-L1 testing is required. Testing to establish MSI/MMR-deficient status is required.